Inter Partes Review: Patent Killer No More?
| dc.citation.epage | 683 | en_US |
| dc.citation.issue | 7 | en_US |
| dc.citation.spage | 680 | en_US |
| dc.citation.volume | 37 | en_US |
| dc.citation.woscount | 0 | en_US |
| dc.contributor.author | Chen, Feng-Chi | en_US |
| dc.contributor.author | Lee, Pin-Shen | en_US |
| dc.contributor.department | 科技法律學院 | zh_TW |
| dc.contributor.department | College of Law | en_US |
| dc.date.accessioned | 2019-08-02T02:18:29Z | |
| dc.date.available | 2019-08-02T02:18:29Z | |
| dc.date.issued | 2019-07-01 | en_US |
| dc.description.abstract | Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community. | en_US |
| dc.identifier.doi | 10.1016/j.tibtech.2019.02.006 | en_US |
| dc.identifier.issn | 0167-7799 | en_US |
| dc.identifier.journal | TRENDS IN BIOTECHNOLOGY | en_US |
| dc.identifier.uri | http://dx.doi.org/10.1016/j.tibtech.2019.02.006 | en_US |
| dc.identifier.uri | https://ir.lib.nycu.edu.tw/handle/11536/152312 | |
| dc.identifier.wosnumber | WOS:000471155300002 | en_US |
| dc.language.iso | en_US | en_US |
| dc.title | Inter Partes Review: Patent Killer No More? | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed to upon submission
- Description: